Rapid Reactions is a video series that provides commentary from key experts summarizing data released at the 2022 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO-GI) focused on gastric, gastroesophageal, and esophageal cancer. Please join Minsig Choi, MD, from Stonybrook University Cancer Center, as he discusses the following 3 pivotal presentations from ASCO-GI 2022:
- Results of the GERCOR NEONIPIGA phase 2 study indicated that neoadjuvant therapy with nivolumab and ipilimumab was feasible and was associated with a high pathologic complete response rate in patients with microsatellite instability/DNA mismatch repair deficiency resectable esophagogastric junction and gastric adenocarcinoma
- Findings of the phase 2 study of FOLFOX plus nab-paclitaxel indicated that the anthracycline-based triplet regimen was associated with a high response rate and expected toxicities in patients with metastatic or advanced unresectable gastric, gastroesophageal junction adenocarcinoma
- Results of the Ni-HIGH study showed that the combination of nivolumab plus trastuzumab and either S-1 or capecitabine plus oxaliplatin was tolerable and demonstrated promising antitumor activity in chemotherapy-naïve patients with HER2-positive advanced gastric cancer
